Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome

After Swissmedic approval of Kymriah (tisagenlecleucel, Novartis, Basel, Switzerland) in 2018 for chimeric antigen receptor T-cell (CAR-T) therapy for adults with relapsed or refractory (r/r) B-lineage acute lymphoblastoid leukemia (ALL) and high-grade B-cell lymphomas after failure of two or more therapy lines, followed by the approval of Yescarta (axicabtagen ciloleucel, Kite/Gilead, Santa Monica, CA) by Swissmedic in 2019, a growing number of Swiss centers have established CAR-T therapy. In addition, CAR-T therapy is currently being explored for other hematologic malignancies, for example, multiple myeloma [1].

Source: Experimental Hematology - July 12, 2020 Category: Hematology Authors: Thomas Pabst, Raphael Joncourt, Evgenii Shumilov, Alexander Heini, Gertrud Wiedemann, Myriam Legros, Katja Seipel, Christof Schild, Katarzyna Jalowiec, Behrouz Mansouri, Michaela Fux, Urban Novak, Naomi Porret, Sacha Zeerleder, Ulrike Bacher Tags: Brief communication Source Type: research